ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay.  Neutrophil elastase is a well-recognised biomarker of lung inflammation and infection in chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis.  The registration of a CE Mark indicates that the ProteaseTag® Active Neutrophil Elastase Immunoassay complies with EU legislation, and enables the company to commercialise the Immunoassay throughout the European market.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “This is a very proud day for everyone at ProAxsis, with the successful registration of our first CE Mark.  We have already had enquiries from a number of pharmaceutical companies concerning the commercial use of our ProteaseTag® Active Neutrophil Elastase Immunoassay in their upcoming clinical trials, and look forward to making the assay more widely available to the respiratory community now that it has its CE Mark.  I would particularly like to acknowledge the work of Dr Charlene Robb, who has led the regulatory efforts that have enabled us to reach this significant milestone.”

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@77.104.171.207.